INmune Bio, Inc. (INMB) Bundle
An Overview of INmune Bio, Inc. (INMB)
General Summary of INmune Bio, Inc. (INMB)
INmune Bio, Inc. was founded on September 25, 2015, in the State of Nevada. The company is a clinical-stage biotechnology firm focused on developing therapies that target the innate immune system to treat various diseases. Its primary product platforms include DN-TNF, which targets soluble TNF for conditions such as Alzheimer's and treatment-resistant depression, and the Natural Killer Cell Priming Platform, which includes INKmune, aimed at enhancing NK cell activity in cancer patients.
As of 2024, INmune Bio has not generated substantial revenue from product sales, reporting only $14,000 in revenue for the nine months ended September 30, 2024, down from $127,000 in the previous year.
Company's Financial Performance in the Latest Financial Reports
For the nine months ending September 30, 2024, INmune Bio reported:
| Metric | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Revenues | $14 | $127 | $(113) |
| Research and Development Expenses | $25,813 | $14,266 | $11,547 |
| General and Administrative Expenses | $7,369 | $7,223 | $146 |
| Total Operating Expenses | $33,182 | $21,489 | $11,693 |
| Net Loss | $(32,864) | $(21,600) | $(11,264) |
In the third quarter of 2024, the company reported no sales, compared to $43,000 in the same quarter of 2023. Research and development expenses increased significantly to approximately $10.1 million, primarily due to advancements in clinical trials.
As of September 30, 2024, INmune Bio had cash and cash equivalents of $33.6 million, reflecting a decrease from $35.8 million at the end of 2023.
Introduction to INmune Bio as a Leader in the Industry
INmune Bio positions itself as a leader in the biotechnology sector, particularly focusing on innate immune therapies. Despite facing significant operating losses and challenges in generating revenue, the company continues to advance its clinical programs for cancer and neurodegenerative diseases, which are critical areas of unmet medical need. The company has been actively raising funds through equity offerings to support its ongoing research and development efforts.
Mission Statement of INmune Bio, Inc. (INMB)
Mission Statement Overview
INmune Bio, Inc. (INMB) is a clinical-stage biotechnology company focused on developing and commercializing therapies aimed at addressing diseases linked to innate immune dysfunction. The mission statement reflects the company's commitment to innovation and excellence in the field of biotechnology.
Core Component 1: Innovation
INmune Bio emphasizes the importance of innovation in its mission. The company invests significantly in research and development, with expenses reaching approximately $25.8 million for the nine months ended September 30, 2024, compared to $14.3 million for the same period in 2023. This financial commitment illustrates the company's dedication to advancing its product platforms, including DN-TNF for Alzheimer’s and treatment-resistant depression, and the Natural Killer Cell Priming Platform aimed at cancer treatments.
Core Component 2: Patient-Centric Approach
Another key aspect of INmune Bio's mission is its patient-centric approach. The company is focused on developing therapies that address significant unmet medical needs. For instance, the Alzheimer’s clinical program has seen increased enrollment, contributing to an additional $10.3 million in expenses for the nine months ended September 30, 2024. This reflects a strategic effort to enhance the quality of life for patients through innovative treatment options.
Core Component 3: Commitment to Excellence
INmune Bio's mission underscores a commitment to excellence in all aspects of its operations. This is evidenced by the company's rigorous clinical trials and adherence to regulatory standards. As of September 30, 2024, INmune Bio's total operating expenses amounted to $33.2 million, reflecting its focus on maintaining high standards in research and operational efficiency. The company also reported a net loss of $32.9 million for the same period, highlighting the financial challenges often faced by biotech firms as they strive for excellence and innovation.
| Financial Metric | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) |
|---|---|---|
| Research and Development Expenses | $25.8 million | $14.3 million |
| General and Administrative Expenses | $7.4 million | $7.2 million |
| Total Operating Expenses | $33.2 million | $21.5 million |
| Net Loss | $32.9 million | $21.6 million |
Vision Statement of INmune Bio, Inc. (INMB)
Vision Statement Overview
INmune Bio, Inc. (INMB) focuses on enhancing the innate immune system to treat diseases where it is not functioning optimally. The company's vision is rooted in a commitment to advancing innovative therapies that target unmet medical needs.
Commitment to Innovation
INmune Bio aims to lead in the development of groundbreaking therapies, particularly in the fields of oncology and neurology. The company is dedicated to utilizing its proprietary technologies, including the DN-TNF product platform and Natural Killer Cell Priming Platform, to create effective treatment options.
Focus on Patient-Centric Solutions
The vision of INmune Bio emphasizes a patient-first approach, striving to improve the quality of life for individuals suffering from chronic diseases. By prioritizing patient needs, the company seeks to deliver therapies that not only treat symptoms but also address the underlying causes of diseases.
Strategic Research and Development
INmune Bio is committed to rigorous research and development, as evidenced by its significant financial investments. For the nine months ended September 30, 2024, the company reported research and development expenses of approximately $25.8 million, compared to $14.3 million in the prior year, reflecting a $10.3 million increase primarily due to its Alzheimer’s clinical program.
| Financial Metric | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Research and Development Expenses | $25.8 million | $14.3 million | $10.3 million increase |
| General and Administrative Expenses | $7.4 million | $7.2 million | $0.2 million increase |
| Total Operating Expenses | $33.2 million | $21.5 million | $11.7 million increase |
| Net Loss | $(32.9) million | $(21.6) million | $(11.3) million increase |
Collaboration and Partnerships
INmune Bio recognizes the importance of strategic collaborations in achieving its vision. The company has entered into partnerships aimed at accelerating the development of its therapeutic candidates. This collaborative approach enhances its research capabilities and broadens the scope of its clinical applications.
Global Impact and Accessibility
INmune Bio envisions a future where its therapies are accessible globally, ensuring that patients around the world benefit from its innovations. The company is working towards regulatory approvals that will facilitate the distribution of its products to a wider audience.
Financial Health and Future Investments
As of September 30, 2024, INmune Bio had cash and cash equivalents of approximately $33.6 million, demonstrating its capacity to fund ongoing research and development initiatives. The company’s financial strategy includes raising additional capital to support its growth and development objectives.
| Financial Metric | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $33.6 million | $35.8 million |
| Accumulated Deficit | $(153.9) million | $(121.0) million |
| Total Stockholders’ Equity | $38.7 million | $37.3 million |
Long-Term Vision
INmune Bio’s long-term vision encompasses a commitment to transforming the landscape of immunotherapy. The company aspires to be at the forefront of medical advancements that harness the power of the immune system to combat various diseases.
Core Values of INmune Bio, Inc. (INMB)
Integrity
Integrity is foundational to INmune Bio, Inc. (INMB), guiding the company's interactions with stakeholders. The commitment to ethical practices ensures trust and transparency in all operations.
In 2024, INmune Bio has implemented rigorous compliance programs and ethical training for employees, reinforcing its dedication to integrity. The company maintains transparency in its financial reporting, as demonstrated by its detailed quarterly disclosures showing net losses of $32.9 million for the nine months ended September 30, 2024.
Innovation
Innovation is at the core of INmune Bio’s mission to develop novel therapies targeting diseases linked to immune dysfunction. The company invests heavily in research and development, with expenses totaling approximately $25.8 million for the nine months ended September 30, 2024, significantly increasing from $14.3 million in the same period in 2023.
Notably, INmune Bio is advancing its product platforms, including DN-TNF for Alzheimer’s and INKmune for cancer therapy. The ongoing clinical trials reflect the company’s commitment to bringing innovative solutions to market.
Collaboration
Collaboration is vital for INmune Bio’s success, fostering partnerships that enhance its research capabilities. The company has engaged in strategic alliances with various academic institutions and biotech partners to leverage expertise and resources.
For instance, INmune Bio's collaboration with the Anthony Nolan Cord Blood Bank in the UK has enabled the company to secure a reliable supply of human umbilical cord mesenchymal stromal cells, which are crucial for its clinical trials. This collaboration underscores the company's strategy to utilize external expertise to bolster its research efforts.
Accountability
Accountability at INmune Bio ensures that the company meets its commitments to stakeholders while being responsible for its financial health. The company’s financial statements indicate a commitment to accountability, detailing comprehensive losses and expenses incurred.
As of September 30, 2024, INmune Bio reported total liabilities of $14.1 million, with a total stockholders' equity of $38.7 million. This financial transparency provides stakeholders with a clear view of the company's fiscal responsibility.
Excellence
Excellence drives INmune Bio’s operations, pushing the company to achieve high standards in research and product development. The focus on clinical quality is evident in the company's rigorous trial protocols and high-quality manufacturing processes.
During the nine months ended September 30, 2024, the company’s research and development costs allocated to its Alzheimer’s program reached $18.8 million, reflecting its commitment to excellence in developing effective treatments.
| Core Value | Description | 2024 Initiatives | Financial Commitment (in millions) |
|---|---|---|---|
| Integrity | Commitment to ethical practices and transparency | Compliance programs, ethical training | $32.9 (net loss) |
| Innovation | Focus on developing novel therapies | Investment in R&D, advancing clinical trials | $25.8 (R&D expenses) |
| Collaboration | Strategic partnerships to enhance capabilities | Alliances with academic institutions | N/A |
| Accountability | Responsibility for commitments and financial health | Transparent financial statements | $14.1 (total liabilities) |
| Excellence | Achieving high standards in operations | Rigorous trial protocols, quality manufacturing | $18.8 (Alzheimer's program) |
INmune Bio, Inc. (INMB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- INmune Bio, Inc. (INMB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of INmune Bio, Inc. (INMB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View INmune Bio, Inc. (INMB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.